Metabolite patterns in blood and urine of people with fibrosing interstitial lung disease and precapillary pulmonary hypertension
Blood and uRine Metabolomics Exploration for Assessing Thoracic Health After Treatment of Group 3 Pulmonary Hypertension
We will see if blood and urine metabolite patterns change in people with fibrosing interstitial lung disease who have precapillary pulmonary hypertension, before and during treatments such as inhaled treprostinil.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 80 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Bron, Rhone) |
| Trial ID | NCT07254338 on ClinicalTrials.gov |
What this trial studies
This observational project collects blood and urine samples from patients with fibrosing interstitial lung disease suspected of having precapillary pulmonary hypertension. Samples are obtained around diagnostic right heart catheterization and during follow-up, including before and after initiation of pulmonary hypertension therapies such as inhaled treprostinil. Metabolomic profiling will compare systemic metabolite patterns with hemodynamic findings and treatment exposure to identify biochemical signatures linked to disease state and treatment response. The protocol is minimally invasive and does not alter standard clinical care.
Who should consider this trial
Good fit: Adults with progressive fibrosing interstitial lung disease who are suspected of having precapillary pulmonary hypertension, are scheduled for hemodynamic confirmation, and can give informed consent for blood and urine sampling.
Not a fit: Patients with other forms of pulmonary hypertension (for example PAH or CTEPH), those not undergoing catheterization, or those unwilling/unable to provide samples are unlikely to gain direct benefit from participation.
Why it matters
Potential benefit: If successful, the work could identify metabolic markers that help predict who benefits from PH treatments or guide more personalized therapy for ILD-related PH.
How similar studies have performed: While inhaled treprostinil has shown clinical benefit in recent trials for ILD‑PH, using metabolomics to track systemic treatment effects in this population is relatively novel and not yet widely validated.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients suffering from progressive interstitial lung disease (ILD) and especially lung fibrosis * Suspicion of precapillar pulmonary hypertension (group 3 PH / ILD-PH) * Patients undergoing cardiac catheterisation for haemodynamic confirmation * Patient who has given informed consent Exclusion Criteria: * Patients suffering from other forms of PH (i.e. PAH, CTEPH, heart failure, multifactorial
Where this trial is running
Bron, Rhone
- Hôpital Cardiologique et Pneumologique Louis Pradel — Bron, Rhone, France (Recruiting)
Study contacts
- Study coordinator: Ségolène TURQUIER
- Email: segolene.turquier@chu-lyon.fr
- Phone: 04 72 35 73 32
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.